We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Anthera's Blisibimod Positive in Phase II Extension Study
Read MoreHide Full Article
Anthera Pharmaceuticals, Inc. (ANTH - Free Report) announced positive top-line data from the extension of a phase II BRIGHT-SC study, evaluating key pipeline candidate, blisibimod for treatment of patients with IgA nephropathy (IgAN).
Notably, the BRIGHT-SC study is randomized, double-blind and placebo-controlled, initiated in June 2013, to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with IgAN.
Anthera’s share price movement shows that the stock has significantly underperformed the industry so far this year. The stock has plunged 73% versus the industry’s 9.4% increase during the period.
The extension of phase II BRIGHT-SC study demonstrated a tendency toward lower proteinuria in blisibimod when compared to placebo-treated patients. The study also showed a trend toward preservation of renal function (eGFR) in patients treated with blisibimod. The candidate was well-tolerated during the study compared with placebo.
The trial was conducted on total 58 patients. Patients enrolled in the study were treated for up to 2 years and had the opportunity to complete at least 60 weeks of treatment. Anthera is planning to share these results with the FDA and proceed with a phase III trial for patients with the same indication.
We remind investors that the company has a mid-stage development candidate, Sollpura, acquired from Eli Lilly and Company (LLY - Free Report) in July 2014. The candidate is being developed for treating patients with low digestive enzyme levels or exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other potential diseases.
The company initiated a phase III SOLUTION study on Sollpura in the third quarter of 2015. In December 2016, the company announced that the study had narrowly missed the primary endpoint of a change in the Coefficient of Fat Absorption (CFA) non-inferiority margin. However, Sollpura achieved a statistical criterion for nitrogen absorption and later on, Anthera too reported positive data from the extension phase of the SOLUTION study earlier in March.
The company currently has no approved products. Hence, the successful development of these candidates is crucial for its portfolio boost.
Aduro Biotech’s loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA’s loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Image: Bigstock
Anthera's Blisibimod Positive in Phase II Extension Study
Anthera Pharmaceuticals, Inc. (ANTH - Free Report) announced positive top-line data from the extension of a phase II BRIGHT-SC study, evaluating key pipeline candidate, blisibimod for treatment of patients with IgA nephropathy (IgAN).
Notably, the BRIGHT-SC study is randomized, double-blind and placebo-controlled, initiated in June 2013, to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with IgAN.
Anthera’s share price movement shows that the stock has significantly underperformed the industry so far this year. The stock has plunged 73% versus the industry’s 9.4% increase during the period.
The extension of phase II BRIGHT-SC study demonstrated a tendency toward lower proteinuria in blisibimod when compared to placebo-treated patients. The study also showed a trend toward preservation of renal function (eGFR) in patients treated with blisibimod. The candidate was well-tolerated during the study compared with placebo.
The trial was conducted on total 58 patients. Patients enrolled in the study were treated for up to 2 years and had the opportunity to complete at least 60 weeks of treatment. Anthera is planning to share these results with the FDA and proceed with a phase III trial for patients with the same indication.
We remind investors that the company has a mid-stage development candidate, Sollpura, acquired from Eli Lilly and Company (LLY - Free Report) in July 2014. The candidate is being developed for treating patients with low digestive enzyme levels or exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other potential diseases.
The company initiated a phase III SOLUTION study on Sollpura in the third quarter of 2015. In December 2016, the company announced that the study had narrowly missed the primary endpoint of a change in the Coefficient of Fat Absorption (CFA) non-inferiority margin. However, Sollpura achieved a statistical criterion for nitrogen absorption and later on, Anthera too reported positive data from the extension phase of the SOLUTION study earlier in March.
The company currently has no approved products. Hence, the successful development of these candidates is crucial for its portfolio boost.
Anthera Pharmaceuticals, Inc. Price
Anthera Pharmaceuticals, Inc. Price | Anthera Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Antheracurrently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. and ACADIA Pharmaceuticals Inc. (ACAD - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aduro Biotech’s loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA’s loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>